1. Transarterial chemoembolization for liver metastases of a pancreatic neuroendocrine neoplasm: a single-center experience.
- Author
-
Nanno, Yoshihide, Toyama, Hirochika, Ueshima, Eisuke, Sofue, Keitaro, Matsumoto, Ippei, Ishida, Jun, Urade, Takeshi, Fukushima, Kenji, Gon, Hidetoshi, Tsugawa, Daisuke, Komatsu, Shohei, Kuramitsu, Kaori, Goto, Tadahiro, Asari, Sadaki, Yanagimoto, Hiroaki, Kido, Masahiro, Ajiki, Tetsuo, and Fukumoto, Takumi
- Subjects
- *
LIVER metastasis , *NEUROENDOCRINE tumors , *CHEMOEMBOLIZATION , *PANCREATIC surgery , *PANCREATIC tumors , *SURGICAL anastomosis - Abstract
Transarterial chemoembolization (TACE) is performed for pancreatic neuroendocrine tumor (PanNEN) liver metastases; however, the safety and efficacy of TACE procedures, especially for patients who have undergone previous pancreatic surgery, have not been established. We reviewed 48 TACE procedures (1–6 procedures/patient) performed on 11 patients with PanNEN liver metastases, including 16 TACE procedures (4–6 procedures/patient) for 3 patients with a history of biliary-enteric anastomosis. The overall tumor objective response rate was 94%. The incidence of Clavien‒Dindo grade ≥ 2 complications was 1/16 (6%) and 1/32 (3%), and the median time to untreatable progression was 31 (14–41) and 27 (2–60) months among patients with and without a history of biliary-enteric anastomosis, respectively. Although validation is needed in future studies, our experiences have shown that TACE treatment is a viable treatment option for PanNEN liver metastases, even after biliary-enteric anastomosis with experienced teams and careful patient follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF